Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Immunotherapy for TNBC: IMpassion130 & KEYNOTE-355

Sara Tolaney • 19 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Atezolizumab Checkpoint Inhibitors Gemcitabine Nab-paclitaxel
IMpassion130

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, outlines the role of immunotherapy in triple-negative breast cancer (TNBC), discussing IMpassion130 (NCT02425891) and KEYNOTE-355 (NCT02819518) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sara Tolaney

1:49
Final OS analysis of sacituzumab govitecan in TROPiCS-02
Sara Tolaney • 2 Jun 2023
1:08
ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC
Sara Tolaney • 2 Jun 2023
1:09
Where are we in sequencing ADCs in HR+ breast cancer?
Sara Tolaney • 2 Jun 2023
1:00
TROPiCS-02: sacituzumab govitecan in HR+/HER2- breast cancer
Sara Tolaney • 2 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals